Abilify (aripiprazole) is a prescription atypical antipsychotic that treats depression, schizophrenia, bipolar disorder, irritability related to autism, and specific Tourette's symptoms. While most ...

It is used to treat adults and adolescents aged 15 years and older who suffer from a disease characterised by symptoms such as hearing, seeing or sensing things which are not there, suspiciousness, ...

The FINANCIAL — Teva Pharmaceutical Industries Ltd., on April 28 announced the launch of the generic equivalent to Abilify (aripiprazole) Tablets, 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg, in the ...

TOKYO & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Proteus Digital Health (Proteus) today announced that the United States Food and Drug Administration (FDA) ...

Abilify Asimtufii, the bipolar I disorder treatment from Otsuka and Lundbeck, has entered the world of CGI animation as part of a multichannel direct-to-consumer (DTC) campaign. The two drugmakers ...

Credit: Thinkstock. Abilify Asimtufii is intended for dosing every 2 months via intramuscular injection in the gluteal muscle. The Food and Drug Administration (FDA) has approved Abilify Asimtufii ® ...

Co confirmed that it has initiated a challenge of the patent listed by Otsuka Pharmaceutical Co., Ltd in connection with its Abilify (aripiprazole) tablets, 2mg, 5mg, 10mg, 15mg, 20mg & 30mg.